Category: M&A / Deals
PharmaSignal — M&A / Deals
Blackstone closes $6.3B fund for life sciences investing
BioPharma Dive
It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.
Otsuka grows in neuroplastogens with $1.225bn Transcend buy
Pharmaphorum
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Lilly puts up to $2.75bn into Insilico alliance
Pharmaphorum
Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
Otsuka picks up PTSD drug with $700M Transcend buy
BioPharma Dive
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly paradigm-shifting therapy in psychiatry.
Novartis targets Xolair successor in buyout of startup Excellergy
BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine.
Merck’s deal for Terns sparks debate over a possible biotech bidding war
BioPharma Dive
Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
BioPharma Dive
If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
BioPharma Dive
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.
RA Capital targets China with latest SPAC deal
BioPharma Dive
The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.
Immutrin raises $87M to advance drug for progressive heart disease
BioPharma Dive
The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, ATTR-CM, that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.